Navigation Links
Massachusetts Institute of Technology IDs new cancer drug target
Date:11/8/2010

ntroduce mutations into DNA. This can lead to drug-resistant tumors. Consistent with this idea, the researchers showed in a companion study that lymphomas with reduced Rev1 levels did not become resistant to chemotherapy following treatment and were much less aggressive in spreading to other parts of the body.

In that study, the researchers treated mice with the drug cyclophosphamide. At first, the drug was effective in mice whose tumors had normal and reduced Rev1, but in both groups, tumors reappeared after about two weeks. This is similar to the relapse that frequently occurs during the treatment of many human cancers.

Those relapsed tumors were then transplanted into a second group of mice. In the second group, drug treatment was strikingly more effective in mice with reduced Rev1. Those mice survived much longer 100 percent of the mice with reduced Rev1 lived for 12 days, whereas some of the mice with normal Rev1 level tumors died in two days and only 40 percent lived for 12 days. These experiments showed that reducing Rev1 levels prevented the tumor cells from acquiring drug resistance and aggressiveness when they relapse so that they can be successfully treated again.

The researchers' discoveries suggest that by inhibiting translesion DNA polymerases, it might be possible to treat difficult cancers that have proven resistant to ordinary chemotherapeutic treatments and also prevent the introduction of new mutations during chemotherapy.

In these studies, the researchers used a technique called RNA interference to block the expression of the genes that code for Rev3 and Rev1, but they were unable to shut off the genes completely.


'/>"/>

Contact: Jennifer Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Massachusetts Hospital Agrees to Pay U.S. $2.79 Million to Resolve False Claims Act Allegations
2. Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
3. Elements Therapeutic Massage Announces Franchise Expansion Plan for Massachusetts
4. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
5. Massachusetts health care reform reviewed as a model for national plan
6. Firefighters Walk Over 60,000 Miles in Blue Cross Blue Shield of Massachusetts' Fitness Challenge
7. Blue Cross Blue Shield of Massachusetts Demonstrates Community Commitment with Fifth William C. Van Faasen Community Service Sabbatical
8. Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract
9. Doctors hard to find for patients in Massachusetts first for-profit health plan
10. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
11. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... (PRWEB) May 05, 2015 With the FCPX ... can quickly and easily add washed color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 90 washed CUBE LUT files. , This ... Monochromatic can give any footage a washed look. , ...
(Date:5/5/2015)... 2015 Private equity consultant and international ... announced that its dental stem cell biobank project, ... again--in April, 2015 –and posted yet another exciting record. ... volume and represents a significant 54% increase over last ... biobank is conducted via the Store-A-Tooth brand. The company ...
(Date:5/5/2015)... Beverly Hills Cosmetic Dentist, Arthur Glosman released a luxury ... sold at the offices of Arthur Glosman DDS, 450 N ... an online store . “I wanted to be one ... care and beauty with a luxurious collection of products designed ... , Dr. Glosman’s Advanced Dental Health + Beauty™ products ...
(Date:5/5/2015)... NCPDP announced today that AmerisourceBergen ... a three-year commitment of strategic support for NCPDP, and ... “AmerisourceBergen has supported our multi-stakeholder forum over 3 decades,” ... is a wonderful continuation and expansion of its commitment ... back to our very first Board of Trustees in ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), ... billion peripheral nerve repair market, reported record revenue of ... 2015 compared to $3.14 million in the year-ago first ... proprietary portfolio of nerve repair products - Avance® ... – and our solid sales execution delivered another record ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... to Nutrition experts, some new ways of getting the ... that omega-6 fatty acids are associated with chronic diseases, ... regular daily diet naturally// includes some of each. ... your omega-3s from fish like sardines, salmon and tuna. ...
... spend more for health care and medications than smokers, ... health hazards. While tobacco is still the nation's principal ... obesity was running a close second. ,For ... Corp. economist Roland Sturm used data from two national ...
... human diet mean people today are more at risk of ... the University of Newcastle believe that changes to the way ... anti-cancer agents. ,The researchers are working on a ... stomach cancer. They are carrying out two trials on people ...
... in hospital who smoke and have a history of ... surveyed almost 400 patients// to find if there was ... classified them into four groups:current tobacco use only, history ... ,The patients with both current tobacco use and past ...
... According to researchers reducing weight and increasing exercise cut ... have elevated blood sugar are known to be at ... serious even life-threatening complications, it would be very useful ... individuals avoid the disease. ,Researchers for the ...
... longtime sufferers. New research shows that a combination of ... the severity and frequency of chronic tension headches, which ... people with mild to moderate head pain that occurs ... six months. Although antidepressants require a prescription, they may ...
Cached Medicine News:
(Date:5/5/2015)...  Adeptus Health Inc. (NYSE: ADPT ) (the ... the previously announced offering of 2,100,000 shares of its ... to be sold by the Company, and 750,329 shares ... Partners (the "Selling Stockholder"), at a price to the ... and the Selling Stockholder have granted the underwriters an ...
(Date:5/5/2015)... BOSTON , May 5, 2015   InspireMD, Inc. ... in embolic protection systems, announced today that it will release ... 31, 2015 on Monday, May 11 th before the ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Symphony family of Pacemakers, Ela presents the ... lighter than a passport, will take your ... technologies, and delivering powerful monitoring. ELA ... dual-chamber and atrial tracking modes in patients ...
Medicine Products: